Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Yitao Gong

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102364011. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2019: 2 papers · 2020: 8 papers · 2021: 2 papers · 2022: 2 papers

Papers 14

  1. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41389-022-00411-9↗
  2. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1155/2022/7353572↗
  3. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  4. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02147-z↗
  5. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.2895↗
  6. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.016↗
  7. HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. Co-author DOI 10.1093/abbs/gmz169↗
  8. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Co-author DOI 10.1177/1073274820915947↗
  9. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13045-020-00958-3↗
  10. Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08301-3↗
  11. ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08335-7↗
  12. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗
  13. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Co-author DOI 10.1097/mpa.0000000000001338↗
  14. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Co-author DOI 10.2147/cmar.s211363↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 14 shared papers, 2019–2022 · strength 1.58
  2. Chen Liu · 14 shared papers, 2019–2022 · strength 1.58
  3. Guopei Luo · 14 shared papers, 2019–2022 · strength 1.58
  4. He Cheng · 11 shared papers, 2019–2022 · strength 1.23
  5. Zhiyao Fan · 11 shared papers, 2019–2021 · strength 1.19
  6. Kaizhou Jin · 11 shared papers, 2019–2021 · strength 1.17
  7. Yunzhen Qian · 10 shared papers, 2020–2022 · strength 1.14
  8. Quanxing Ni · 8 shared papers, 2019–2021 · strength 0.85
  9. Chao Yang · 4 shared papers, 2019–2020 · strength 0.39
  10. Yesiboli Tasiheng · 2 shared papers, 2022 · strength 0.27
  11. Yusheng Chen · 2 shared papers, 2022 · strength 0.27
  12. Xu Wang · 2 shared papers, 2022 · strength 0.27
  13. Xuan Lin · 2 shared papers, 2022 · strength 0.27
  14. Zhengjie Dai · 2 shared papers, 2022 · strength 0.27
  15. Xuan Zou · 2 shared papers, 2022 · strength 0.27
  16. Kun Fan · 2 shared papers, 2019–2020 · strength 0.19
  17. Yu Liu · 1 shared paper, 2021 · strength 0.12
  18. Weiding Wu · 1 shared paper, 2021 · strength 0.12
  19. Jin Xu · 1 shared paper, 2020 · strength 0.11
  20. Xu He · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.